El Grupo Menarini y Ryvu Therapeutics presentan, en la reunión anual de la ASH de 2026, los primeros datos clínicos del estudio de fase II JASPIS-01 sobre el dapolsertib (MEN1703, SEL24) en pacientes con linfoma no Hodgkin de células B agresivo, en recaída o refractario, que han recibido...
Hence then, the article about el grupo menarini y ryvu therapeutics presentan los primeros datos del estudio jaspis 01 sobre dapolsertib was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( El Grupo Menarini y Ryvu Therapeutics presentan los primeros datos del estudio JASPIS-01 sobre dapolsertib )
Also on site :
- In 1912, a Manhattan factory sold a cream-filled chocolate cookie to a single grocer in New Jersey; decades later, over 500 billion Oreos have been sold
- JCPenney’s ‘Delicate’ Pink Sapphire Pendant Necklace Is a ‘Beautiful’ Holiday Gift, Now 79% Off
- Southeast Asia shouldn’t copy the U.S. healthcare model, says Walgreens Boots Alliance’s APAC head: ‘It saves your life, but it’s not very healthy’